Overview: The Foundation of Modern Genetic Medicines

As an expert biology specialist with many years of experience at CD BioGlyco, we recognize that the precise, high-purity synthesis of therapeutic oligonucleotides is not merely a service—it is the critical foundation upon which the next generation of genetic medicines is built. Therapeutic oligonucleotides, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and therapeutic messenger RNAs (mRNAs), represent a paradigm shift in drug development, enabling the modulation of gene expression with unprecedented specificity.

Core Technologies: Precision and Innovation in Nucleic Acid Manufacturing

We leverage cutting-edge synthetic platforms to ensure the highest quality for your therapeutic molecule. Our approach encompasses both established and emerging methodologies to handle the complexity and scale of modern oligonucleotide therapeutics.

• Advanced Chemical Synthesis (Phosphoramidite Method)
  The foundation of our expertise lies in the highly optimized solid-phase phosphoramidite chemistry. This iterative cycle is essential for large-scale, high-fidelity production of DNA and RNA sequences. We have developed proprietary enhancements to this process, focusing on:
  • High coupling efficiency: Maximizing the yield and purity of each synthetic step, which is particularly crucial for oligos exceeding 50 bases.
  • Complex chemical modifications: Seamless integration of critical stability and efficacy-enhancing modifications, such as phosphorothioate (PS) backbone linkages, 2'-O-methyl (2'-OMe), 2'-fluoro (2'-F), and LNA/BNA nucleosides, all of which are vital for improving nuclease resistance and target affinity of ASOs and siRNAs.
• Emerging Enzymatic Synthesis (Enzymatic DNA/RNA Synthesis)
  For ultra-long sequences and certain high-throughput applications, we are pioneering the use of enzymatic synthesis (ENDS/ERS), which harnesses the inherent precision of polymerases like terminal deoxynucleotidyl transferase (TdT) coupled with reversible terminators. This technology promises to overcome the size and cumulative error rate limitations associated with chemical methods, offering a path to synthesize longer, more complex constructs with potentially higher fidelity and reduced reliance on toxic solvents (consistent with advancements in the field).

A Complete Portfolio of Therapeutic Oligonucleotides

A rigorously stage-gated synthesis workflow is meticulously executed to guarantee the transparent, high-fidelity production of clinical-grade oligonucleotides. During the core solid-phase synthesis, each phosphoramidite cycle—detritylation, coupling, capping, and oxidation/sulfurization—is continuously monitored by automated systems to maintain precise reaction kinetics. Subsequently, cleavage & deprotection carefully liberate the sequence from its solid support while removing protecting groups, a delicate operation critical for preserving sensitive modifications. The definitive purification & QC phase then employs high-resolution techniques such as IE-HPLC or RP-HPLC to isolate the full-length product, followed by stringent analytical confirmation via mass spectrometry and analytical HPLC.

Workflow

Publication Data

Applications

• Exploratory Research on Mechanisms of Action
  It provides the high-purity materials necessary for foundational studies into how oligonucleotides interact with biological targets, such as mRNA or proteins, which is crucial for validating their intended activity.
• Probe Development for Diagnostic and Analytical Applications
  Custom-synthesized oligonucleotides serve as essential tools for creating highly specific probes used in diagnostic assays, target validation, and various analytical techniques to study biological pathways.
• Supply for Non-Clinical and Safety Assessment Studies
  The service ensures the reliable production of oligonucleotides in the quantities and quality required for comprehensive pharmacokinetic, pharmacodynamic, and toxicology evaluations in research settings.
• Biomarker Discovery and Target Validation Efforts
  Researchers utilize synthesized oligonucleotides in experiments to identify and validate novel biomarkers and molecular targets, a critical step in the early stages of investigative programs.
• Process Development and Scaling for Manufacturing
  The service supports activities focused on transitioning a synthesis protocol from a small research scale to a level suitable for producing larger quantities under controlled conditions for broader research use.

Advantages

• Unparalleled Purity and Quality
  We guarantee industry-leading purity levels, achieved through a combination of ultra-efficient synthesis cycles and rigorous multi-stage HPLC purification.
• Expertise in Complex Modifications
  The efficacy of modern therapeutic oligos is dependent on sophisticated chemical modifications (e.g., novel sugar analogs, complex ligands, unique prodrug assemblies).
• Consultative Partnership
  We operate as an extension of your research team. Our scientific specialists provide pre-synthesis consultation and troubleshooting support throughout your entire development lifecycle.
• Accelerated Turnaround Times without Compromising Quality
  We operate a highly optimized workflow that integrates lean manufacturing principles with state-of-the-art synthesis and purification instrumentation. This allows us to offer industry-leading turnaround times for both standard and complex modified oligonucleotides, significantly accelerating your research and development timelines.
• Extensive Experience with Challenging Sequences and Chemistries
  Our team possesses deep expertise in synthesizing and modifying notoriously difficult sequences, such as those with high GC content, repetitive motifs, or long lengths. We have a proven track record of successfully handling complex chemistries, including multiple, diverse modifications within a single oligonucleotide strand.

Frequently Asked Questions

Customer Review

• "We rely on CD BioGlyco for all our complex siRNA/LNA chimera synthesis. Their Dual-HPLC purification consistently delivers the highest purity we've tested, which has significantly reduced our non-specific toxicity in in vivo models."

— Manager, Target Validation Department

• "The quality of the saRNA they produced for our novel vaccine platform was outstanding. High capping efficiency and excellent structural integrity made the in vitro and in vivo translation results highly repeatable. A true partner in RNA therapeutics."

— Lead Scientist, RNA Immunology

• "Their willingness to take on our custom PMO modifications, which other suppliers declined, was remarkable. The process development work was fast, and the final material quality was exactly as promised."

— Principal Investigator, Rare Disease Research

Associated Services

Our therapeutic oligonucleotide synthesis service provides precise manufacturing of nucleic acid therapeutics, demonstrating our expertise in biomolecular production. Building upon this foundation, we offer a comprehensive Custom Deoxyribonucleic Acid (DNA) Synthesis Service that includes chemical synthesis, enzymatic assembly, and hybrid approaches to meet diverse research and development requirements for tailored genetic materials.

CD BioGlyco stands as your dedicated, expert partner in the rapidly evolving landscape of genetic medicine. Our therapeutic oligonucleotide synthesis service combines over 20 years of scientific expertise, state-of-the-art technology (including cutting-edge enzymatic methods), and a commitment to unparalleled product purity and customer partnership. If you want to obtain the essential, high-quality nucleic acid components, please do not hesitate to contact our expert team.